EXEL · NASDAQ · STOCK
Exelixis (EXEL) Stock Analysis
$58.35
52W $33.76 – $59.72
67/100
$14.67B
17.7
0.42
Is EXEL Bullish or Bearish?
Bullish.
Innellis AI committee rates Exelixis (EXEL) Buy with a composite score of 67/100
, based on 6 analysts with 67% agreement.
Last updated September 20, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +8.28 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -11.72 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 20, 2026
Overall Committee Score
67/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 3%
of 192 Healthcare peers
Value Analyst
neutral
59
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 42.5% shows genuine earnings power backing the valuation
− Price-to-book of 5.4x prices in significant intangible value
Growth Analyst
bullish
72
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 52.7% YoY
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
55
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2518.64)
Investment Thesis Evolution
Committee score moved marginally from 66.7 to 66.7.
Comparing 2026-09-19 to 2026-09-20 (1 day apart).
Technical Analysis
RSI (14)
62.4
Neutral
MACD Histogram
0.041
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.75
Inside Bands
Price vs Moving Averages
EMA 9
$57.45
Above
EMA 21
$56.65
Above
EMA 50
$55.29
Above
EMA 200
$49.43
Above
Fundamental Analysis
Valuation
63
Growth
82
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
17.7×
P/B Ratio
7.94×
PEG Ratio
0.33
Dividend Yield
0.00%
52W High
$59.72
52W Low
$33.76
Quality & Growth
ROE
3620.8%
ROA
2751.2%
Gross Margin
9648.3%
Operating Margin
3988.3%
Revenue Growth YoY
—
Debt / Equity
0.09
AI Fundamental Assessment
P/E ratio of 17.7 (inexpensive relative to a 15-40x range); Price-to-book of 7.9x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 36.2%; Return on assets of 27.5%; Net margin of 35.3%; Gross margin of 96.5%; Current ratio of 3.46 (healthy short-term liquidity); Debt-to-equity of 0.09; Free cash flow per share is positive (4.62); Most recent quarter beat estimates by 2.3%; 5 consecutive earnings beats; EPS growth accelerating (-10.2% -> +3.8% QoQ); Average YoY EPS growth of 26.1%; Analyst estimates falling over recent quarters
Get the Full EXEL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →